Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-004991-31
    Sponsor's Protocol Code Number:MK3475-252
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-04-25
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-004991-31
    A.3Full title of the trial
    A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
    Estudio de fase 3 aleatorizado, doble ciego y controlado con placebo de pembrolizumab (MK 3475) en combinación con epacadostat o placebo en sujetos con melanoma irresecable o metastásico (Keynote 252 / ECHO 301).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase 3 Study of Epacadostat and Pembrolizumab in Melanoma
    Estudio de fase 3 de epacadostat y pembrolizumab en el melanoma
    A.3.2Name or abbreviated title of the trial where available
    Phase 3 Study of Epacadostat and Pembrolizumab in Melanoma
    Estudio de fase 3 de epacadostat y pembrolizumab en el melanoma
    A.4.1Sponsor's protocol code numberMK3475-252
    A.5.4Other Identifiers
    Name:.Number:INCB 24360-301
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorIncyte Corporation
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    B.4.2CountryUnited States
    B.4.1Name of organisation providing supportIncyte Corporation
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMerck Sharp & Dohme de España S.A.
    B.5.2Functional name of contact pointInvestigación Clínica
    B.5.3 Address:
    B.5.3.1Street AddressC/ Josefa Valcárcel, 38
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28027
    B.5.3.4CountrySpain
    B.5.4Telephone number+34913210600
    B.5.5Fax number+34913210590
    B.5.6E-mailensayos_clinicos@merck.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Keytruda
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Sharp and Dohme, Ltd
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePembrolizumab
    D.3.2Product code MK-3475
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPEMBROLIZUMAB
    D.3.9.1CAS number 1374853-91-4
    D.3.9.2Current sponsor codeMK-3475
    D.3.9.3Other descriptive nameAnti-PD-1 monoclonal antibody
    D.3.9.4EV Substance CodeSUB167136
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameepacadostat
    D.3.2Product code INCB024360
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNepacadostat
    D.3.9.2Current sponsor codeINCB024360
    D.3.9.3Other descriptive nameINCB024360
    D.3.9.4EV Substance CodeSUB117263
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameepacadostat
    D.3.2Product code INCB024360
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNepacadostat
    D.3.9.2Current sponsor codeINCB024360
    D.3.9.3Other descriptive nameINCB024360
    D.3.9.4EV Substance CodeSUB117263
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Melanoma
    Melanoma
    E.1.1.1Medical condition in easily understood language
    melanoma
    Melanoma
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level LLT
    E.1.2Classification code 10053571
    E.1.2Term Melanoma
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level LLT
    E.1.2Classification code 10027481
    E.1.2Term Metastatic melanoma
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the progression-free survival (PFS) of the combination of pembrolizumab and epacadostat versus pembrolizumab and placebo (i.e. 2 treatment groups) based on RECIST 1.1 by independent central review; and To compare overall survival (OS) of the 2 treatment groups.
    comparar la supervivencia sin progresión (SSP) con la combinación de pembrolizumab y epacadostat en comparación con pembrolizumab y placebo (es decir, 2 grupos de tratamiento) basándose en los RECIST 1.1 mediante revisión central independiente.
    E.2.2Secondary objectives of the trial
    To compare the objective response rate (ORR) of the 2 treatment groups based on RECIST 1.1 by independent central review; To evaluate the safety and tolerability of the 2 treatment groups; To evaluate the duration of response (DOR) of the 2 treatment groups based on RECIST 1.1 by independent central review; and To evaluate the pharmacokinetics (PK) and anti-pembrolizumab antibodies of pembrolizumab and epacadostat administered concomitantly.
    Comparar la tasa de respuesta objetiva (TRO) de los dos grupos de tratamiento basándose en los RECIST 1.1 mediante revisión central independiente. Evaluar la seguridad y la tolerabilidad en los dos grupos de tratamiento. Evaluar la duración de la respuesta (DR) en los dos grupos de tratamiento basándose en los RECIST 1.1 mediante revisión central independiente; y evaluar la farmacocinética (FC) y los anticuerpos antipembrolizumab tras la administración concomitante de pembrolizumab y epacadostat.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Merck will conduct Future Biomedical Research on DNA (blood) specimens collected during this clinical trial. Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol (as part of the main trial) and will only be conducted on specimens from appropriately consented subjects. The objective of collecting specimens for Future Biomedical Research is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer, more effective drugs, and/or to ensure that subjects receive the correct dose of the correct drug at the correct time.
    Merck realizará investigaciones biomédicas futuras con las muestras obtenidas para tal finalidad durante este ensayo clínico. Estas investigaciones tendrán por objeto el análisis de biomarcadores con el fin de abordar aspectos nuevos que no se describen en otras partes del protocolo (como parte del ensayo principal) y solo se llevarán a cabo en muestras de los pacientes que hayan otorgado el consentimiento correspondiente. El objetivo de la obtención de muestras para investigaciones biomédicas futuras es estudiar e identificar biomarcadores que proporcionen información a los científicos sobre las enfermedades y sus tratamientos. El objetivo último es utilizar tal información para desarrollar fármacos más seguros y eficaces o para garantizar que los sujetos reciban la dosis correcta del fármaco en el momento preciso.
    E.3Principal inclusion criteria
    1. Have histologically or cytologically confirmed melanoma.
    2. Have unresectable Stage III or Stage IV melanoma, as per AJCC staging system not amenable to local therapy.
    3. Have been untreated for advanced or metastatic disease except as follows.
    a. BRAF V600 mutant melanoma may have received standard of care targeted therapy (e.g. BRAF/MEK inhibitor, alone or in combination) and be eligible for this study
    Note: Targeted therapy is not required for eligibility.
    b. Prior adjuvant or neoadjuvant melanoma therapy is permitted if it was completed at least 4 weeks before randomization and all related adverse events have either returned to baseline or stabilized.
    c. Prior adjuvant therapy containing immunotherapy such as interferon or anti-CTLA-4 therapy will only be permitted if relapse did not occur during treatment or within 6 months of treatment discontinuation.
    d. Prior anti-PD-1, anti-PD-L1, or IDO1 inhibitors are excluded.
    4. Have documentation of V600-activating BRAF mutation status or consent to BRAF V600 mutation testing during the screening period.
    5. Have laboratory and medical history parameters within Protocol-defined range. The screening laboratory tests below must be ? 7 days before treatment initiation.
    6. Have the presence of at least one measurable lesion by CT or MRI per RECIST 1.1 criteria as determined by the local site investigator/radiology assessment. Cutaneous lesions and other superficial lesions that are detectable only by physical examination are not considered measurable lesions for the purposes of this protocol, but may be considered as non-target lesions.
    a. If subjects have only 1 measurable lesion per RECIST 1.1, the biopsy specimen should be obtained from the non-target lesion or archival tissue.
    b. If subjects have only 1 measurable lesion per RECIST 1.1, this lesion should not have been in the field of prior irradiation unless there is documented progression of the lesion(s).
    7. Provide a baseline tumor biopsy
    a. Subjects must submit the tumor sample during screening for PD-L1 expression testing at a central pathology laboratory. Subjects will be eligible to participate regardless of the level of PD-L1 expression, but will be stratified by PD-L1 expression level. Subjects who do not submit a sample adequate for PD-L1 determination will not be randomized. Subjects with an inadequate archival sample may obtain a new biopsy and subjects with an inadequate newly obtained biopsy may undergo re-biopsy at the discretion of the investigator. The biopsy may not be obtained from a lone target lesion.
    Note: Archival is defined as obtained since last systemic therapy for cancer or newly obtained.
    8. Have resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). If subject received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
    9. Be male or female subjects, age 18 years or older on day of signing consent.
    10. Provide written informed consent/assent for the study. The subject may also provide consent/assent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.
    11. Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
    12. If female of childbearing potential (Section 5.7.2), must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
    13. If female of childbearing potential (Section 5.7.2), must be willing to use an adequate method of contraception as outlined in Section 5.7.2 ? Contraception, for the course of the study through 120 days after the last dose of study medication.
    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
    14. If male of childbearing potential (Section 5.7.2), must agree to use an adequate method of contraception as outlined in Section 5.7.2- Contraception, and not to donate sperm starting with the first dose of study therapy through 120 days after the last dose of study therapy.
    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
    1. Tener melanoma confirmado histológica o citológicamente.
    2. Tener melanoma en estadio III o IV irresecable, según el sistema de estadificación del AJCC, no susceptible de tratamiento local.
    3. No haber recibido tratamiento para la enfermedad metastásica, con las excepciones siguientes.
    a. El melanoma con mutación V600 del BRAF puede haberse sometido a tratamiento dirigido convencional (p. ej., inhibidor de BRAF/MEK, solo o en combinación) y ser elegible para este estudio
    Nota: el tratamiento dirigido no es un requisito de elegibilidad.
    b. Se permite el tratamiento neoadyuvante o adyuvante previo del melanoma si se completó al menos 4 semanas antes de la aleatorización y todos los acontecimientos adversos relacionados se han estabilizado o remitido hasta el estado basal.
    c. Sólo se permitirá el tratamiento adyuvante previo que contenga inmunoterapia como interferón o tratamiento con anti CTLA 4 si no se produjo recidiva durante el tratamiento o en los 6 meses siguientes a su interrupción.
    d. Se excluyen los anti PD 1, anti PD L1 o inhibidores de la IDO1 previos.
    4. Tener documentada la presencia de mutación activadora V600 en BRAF o aceptar que se analice si existe mutación V600 en el BRAF durante el período de selección.
    5. Tener valores analíticos y antecedentes médicos situados dentro de los intervalos definidos en el protocolo. Los análisis de selección enumerados a continuación deberán realizarse ? 7 días antes del inicio del tratamiento.
    6. Tener al menos una lesión medible por TC o RM según los criterios RECIST 1.1 determinada por valoración del investigador del centro o radiológica. Las lesiones cutáneas y otras lesiones superficiales que sólo sean detectables mediante exploración física no se consideran medibles para los fines de este protocolo, pero pueden considerarse lesiones no diana.
    a. Si los sujetos sólo tienen una lesión medible según los RECIST 1.1, la muestra de biopsia debe obtenerse de la lesión no diana o de tejido archivado.
    b. Si los sujetos sólo tienen 1 lesión medible según los RECIST 1.1, esta lesión no debe haber estado en el campo de una irradiación previa, a menos que exista progresión documentada de la lesión o lesiones.
    7. Facilitar una biopsia tumoral basal.
    a. Los sujetos deberán proporcionar la muestra tumoral durante la selección para que se analice la expresión de PD L1 en un laboratorio de anatomía patológica central. Los sujetos serán elegibles para participar sea cual sea el nivel de expresión del PD L1, pero se estratificarán en función de ese nivel de expresión. No se aleatorizará a los sujetos que no proporcionen una muestra adecuada para la determinación del PD L1. Los sujetos cuya muestra archivada sea insuficiente pueden someterse a una nueva biopsia, y los sujetos con una nueva biopsia insuficiente pueden someterse a otra biopsia a criterio del investigador. La biopsia no puede obtenerse de una lesión diana solitaria.
    Nota: se considera archivada la muestra obtenida desde el último tratamiento sistémico del cáncer u obtenida nueva.
    8. Presentar resolución de los efectos tóxicos del tratamiento previo más reciente hasta un grado 1 o inferior (excepto la alopecia). Si el sujeto se ha sometido a cirugía mayor o > 30 Gy de radioterapia, deberá haberse recuperado de la toxicidad y/o las complicaciones de la intervención.
    9. Ser tanto varón como mujer y tener 18 o más años de edad en el día de la firma del consentimiento.
    10. Dar el consentimiento o asentimiento informado por escrito para el estudio. El sujeto también puede dar el consentimiento o asentimiento para investigación biomédica futura. No obstante, puede participar en el ensayo principal sin hacerlo en la investigación biomédica futura.
    11. Tener un estado funcional del Eastern Cooperative Oncology Group (ECOG) de 0 ó 1.
    12. Las mujeres en edad fértil (sección 5.7.2) deberán dar negativo en una prueba de embarazo en orina o suero en las 72 horas previas a la administración de la primera dosis de medicación del estudio. Si el resultado de la prueba en orina es positivo o no pueda confirmarse que es negativo, se precisará una prueba de embarazo en suero.
    13. Si la mujer está en edad fértil (sección 5.7.2), deberá estar dispuesta a utilizar un método anticonceptivo adecuado como se indica en la sección 5.7.2 Anticoncepción, durante el estudio y hasta 120 días después de la última dosis de la medicación del estudio.
    Nota: la abstinencia es aceptable si se adapta al modo de vida y es el método anticonceptivo preferido de la paciente.
    14.Los varones fértiles (sección 5.7.2) deberán comprometerse a utilizar un método anticonceptivo adecuado como se indica en la sección 5.7.2 Anticoncepción, y a no donar semen, desde la primera dosis del tratamiento del estudio y hasta 120 días después de la última dosis del tratamiento del estudio.
    Nota: la abstinencia es aceptable si se adapta al modo de vida y es el método anticonceptivo preferido del sujeto.
    E.4Principal exclusion criteria
    1. Has received prior systemic treatment for unresectable or metastatic melanoma (except BRAF directed therapy as noted in inclusion criteria #3).
    2. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or IDO1 inhibitor or any other antibody or drug specifically targeting checkpoint pathways other than anti-CTLA-4 which is permitted in the adjuvant setting.
    3. Has received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer) before study Day 1 or not recovered (? Grade 1 or at baseline) from AEs due to previously administered agents. Exception to this rule would be use of denosumab, which is not excluded.
    Note: Subjects with ? Grade 2 neuropathy are an exception and may enroll.
    4. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment.
    5. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include early stage cancers (carcinoma in situ or stage 1) treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy.
    6. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks before the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases confirmed by repeat imaging, and have not required steroids for at least 14 days before study treatment.
    7. Has ocular melanoma.
    8. Has known hypersensitivity to active substances or any of their excipients including previous clinically significant hypersensitivity reaction to treatment with another monoclonal antibody.
    9. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
    10. Has an active infection requiring systemic therapy.
    11. Has known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
    12. Has known history of or is positive for Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA [qualitative] is detected).
    13. Has evidence of interstitial lung disease or active, noninfectious pneumonitis.
    14. Has received prior radiotherapy within 2 weeks of therapy. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (? 2 weeks of RT) to non-CNS disease.
    15. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.
    16. Has received live vaccine within 30 days before the first dose of study treatment.
    17. Has received monoamine oxidase inhibitors within the 21 days before screening.
    18. Has any history of Serotonin Syndrome after receiving serotonergic drugs.
    19. Has presence of a gastrointestinal condition that may affect drug absorption.
    20. Has a history or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful. Screening QTc interval > 480 msec is excluded (corrected by Fredericia or Bazett formula). In the event that a single QTc is > 480 milliseconds, the subject may enroll if the average QTc for the 3 ECGs is < 480 milliseconds.
    Read to the protocol
    1.Ha recibido tratamiento sistémico previo para el melanoma irresecable o metastásico (excepto el tratamiento dirigido al BRAF señalado en el criterio de inclusión 3).
    2.Ha recibido tratamiento previo con un anti PD 1, anti PD L1, anti PD L2, anti?CD137 o inhibidor de la IDO1, o cualquier otro anticuerpo o fármaco dirigido específicamente a vías de puntos de control distintas de los anti CTLA 4, que se permite en el contexto adyuvante.
    3.Ha recibido tratamiento adyuvante previo, anticuerpo monoclonal o un fármaco o dispositivo en investigación en las 4 semanas o 5 semividas (el período más largo) previas al día 1 del estudio o no se haya recuperado (a un grado ? 1 o al estado basal) de AA debidos a fármacos administrados previamente. La excepción a esta regla sería el uso de denosumab, que no está excluido.Nota: los sujetos con neuropatía de grado ? 2 son una excepción y pueden incluirse.
    4.Tiene un diagnóstico de inmunodeficiencia o está recibiendo tratamiento sistémico crónico con esteroides (en dosis superiores a 10 mg diarios de equivalente de prednisona) o cualquier otra forma de tratamiento inmunodepresor en los 7 días previos a la primera dosis del tratamiento en estudio.
    5.Tiene otro tumor maligno conocido que está
    progresando o exige tratamiento activo. Son excepciones los cáncer en estadio precoz (carcinoma in situ o estadio 1) tratados con intención curativa, carcinoma basocelular de la piel, carcinoma epidermoide de piel, cáncer de cuello uterino in situ o cáncer de mama in situ sometido a tratamiento potencialmente curativo.
    6.Tiene metástasis activas conocidas en el sistema nervioso central (SNC) y/o meningitis carcinomatosa. Los sujetos con metástasis cerebrales tratadas previamente pueden participar siempre que estén estables (sin signos de progresión en los estudios de imagen durante al menos 4 semanas antes de la primera dosis de tratamiento del estudio y con regreso de los síntomas neurológicos a la situación basal), no tengan indicios de metástasis cerebrales nuevas o en crecimiento confirmadas mediante estudios de imagen repetidos y no hayan necesitado esteroides durante al menos 14 días antes del tratamiento del estudio.
    7.Tiene melanoma ocular.
    8.Tiene hipersensibilidad conocida a los principios activos o a cualquiera de sus excipientes, incluida una reacción de hipersensibilidad de importancia clínica previa al tratamiento con otro anticuerpo monoclonal.
    9.Tiene una enfermedad autoinmunitaria activa que ha precisado en los dos últimos años tratamiento sistémico (es decir, fármacos modificadores de la enfermedad, corticosteroides o inmunodepresores). El tratamiento de reposición (p. ej., tratamiento sustitutivo de tiroxina, insulina o corticosteroides en dosis fisiológicas por insuficiencia suprarrenal o hipofisaria, etc.) no se considera una forma de tratamiento sistémico.
    10.Tiene una infección activa que exige tratamiento sistémico.
    11.Tiene antecedentes de infección por el virus de la inmunodeficiencia humana (VIH) (anticuerpos contra el VIH 1 ó 2).
    12.Tiene antecedentes conocidos o análisis positivo para la hepatitis B (reactividad para el AgHBs) o la hepatitis C (se detecta ARN del VHC [cualitativo]).
    13.Tiene signos de neumopatía intersticial o de neumonitis no infecciosa activa.
    14.Ha recibido radioterapia en las 2 semanas previas al tratamiento. Los sujetos deberán haberse recuperado de todos los efectos tóxicos relacionados con la radiación, no precisar corticosteroides y no haber sufrido neumonitis por radiación. Se permite un lavado de 1 semana en caso de radiación paliativa (? 2 semanas de RT) para enfermedad que no afecte al SNC.
    15.Está embarazada o en periodo de lactancia, o tiene intención de concebir o engendrar un hijo dentro del período previsto del estudio, desde la visita de selección hasta 120 días después de la última dosis del tratamiento del estudio.
    16.Ha recibido una vacuna de microorganismos vivos en los 30 días previos a la primera dosis de tratamiento del estudio.
    17.Ha recibido inhibidores de la monoaminoxidasa en los 21 días previos a la selección.
    18.Tiene antecedentes de síndrome serotoninérgico después de recibir fármacos serotoninérgicos.
    19.Presenta un proceso digestivo que puede afectar a la absorción de fármacos.
    20.Tiene antecedentes o presencia actual de un electrocardiograma (ECG) anómalo que es clínicamente significativo en opinión del investigador. Se excluye un intervalo QT en la selección > 480 ms (corregido por la fórmula de Fredericia o Bazett). En caso de que un solo QTc sea > 480 milisegundos, puede incluirse al sujeto si el QTc promedio de los 3 ECG es < 480 milisegundos.
    Leer en el Protocolo
    E.5 End points
    E.5.1Primary end point(s)
    The dual primary endpoints are PFS and OS.
    ? Progression-free survival, defined as the time from date of randomization until the earliest date of disease progression, as determined by independent central review of objective radiographic disease assessments per RECIST 1.1, or death from any cause, whichever comes first.
    ? Overall survival, defined as the time from date of randomization to date of death due to any cause.
    The study is considered to have met its study objective if the combination is superior to pembrolizumab and placebo in either PFS or OS.
    Los dos criterios de valoración principales son la SSP y la SG.
    ?La supervivencia sin progresión se define como el tiempo desde la fecha de aleatorización hasta la fecha más temprana de progresión de la enfermedad, determinada mediante revisión central independiente de valoraciones radiográficas objetivas de la enfermedad según los RECIST 1.1, o como el fallecimiento por cualquier causa, lo que antes ocurra.
    ?La supervivencia global se define como el tiempo desde la fecha de aleatorización hasta la fecha del fallecimiento por cualquier causa.
    Se considera que el estudio ha cumplido su objetivo si la combinación es superior al pembrolizumab y el placebo en la SSP o la SG.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Two interim analyses (IA1, IA2) will be performed in this study:
    ? IA1 to be performed when ~420 PFS events have been observed
    ? IA 2 to be performed when ~270 OS events have occurred
    ? Final Analysis to be performed when ~360 OS events have occurred
    Dos análisis intermedios (IA1, IA2) se llevarán a cabo en el estudio.
    ?AI 1 : Se realizará cuando se hayan observado ~ 420 episodios de SSP
    ?AI 2: se realizará cuando hayan ocurrido ~ 270 episodios de SG.
    ?Análisis final: se realizará cuando hayan ocurrido ~ 360 episodios de SG
    E.5.2Secondary end point(s)
    ? Objective response rate, defined as the proportion of subjects who have best response as complete response (CR) or partial response (PR). Responses are based on independent central review using RECIST 1.1.
    ? Duration of response (DOR) determined by disease assessment defined as the time from the earliest date of qualifying response until earliest date of disease progression or death from any cause, whichever comes first. Response will be determined by independent central review using RECIST 1.1.
    ?Tasa de respuesta objetiva, definida como la proporción de sujetos cuya mejor respuesta es una respuesta completa (RC) o parcial (RP). Las respuestas se basan en la revisión central independiente basada en los criterios RECIST 1.1.
    ?Duración de la respuesta (DR) determinada por la valoración de la enfermedad, definida como el tiempo desde la primera fecha con calificación de respuesta hasta la primera fecha de progresión de la enfermedad o fallecimiento por cualquier causa, lo que antes ocurra. La respuesta se determinará mediante revisión central independiente basada en los RECIST 1.1.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Two interim analyses (IA1, IA2) will be performed in this study:
    ? IA1 to be performed when ~420 PFS events have been observed
    ? IA 2 to be performed when ~270 OS events have occurred
    ? Final Analysis to be performed when ~360 OS events have occurred
    Dos análisis intermedios (IA1, IA2) se llevarán a cabo en el estudio.
    ?AI 1 : Se realizará cuando se hayan observado ~ 420 episodios de SSP
    ?AI 2: se realizará cuando hayan ocurrido ~ 270 episodios de SG.
    ?Análisis final: se realizará cuando hayan ocurrido ~ 360 episodios de SG
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis Yes
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA44
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Canada
    Chile
    Denmark
    France
    Germany
    Ireland
    Israel
    Italy
    Korea, Republic of
    Mexico
    Netherlands
    New Zealand
    Poland
    Russian Federation
    South Africa
    Spain
    Sweden
    Switzerland
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The overall trial ends when the last subject completes the last study-related phone-call or visit, discontinues from the trial or is lost to follow-up (i.e. the subject is unable to be contacted by the investigator).
    El ensayo en su conjunto termina cuando el último sujeto complete la última llamada telefónica o visita del estudio, se retire del ensayo o se pierda al seguimiento (es decir, cuando el investigador no pueda ponerse en contacto con el sujeto).
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months11
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 450
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 150
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state48
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 252
    F.4.2.2In the whole clinical trial 600
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The treatment period with the combination therapy will continue every 21 days for up to 35 infusions ,approximately 2 years ,as long as subjects are receiving benefit from treatment and have not had disease progression or met any criteria for study withdrawal. Subjects who stop study treatment with SD or better may be eligible for up to 1 year ,17 infusions,of additional combination therapy if they experience disease progression after stopping the combination study treatment.
    El período de tratamiento combinado continuará cada 21 días hasta que completar 35 infusiones,alrededor de 2 años siempre que los sujetos obtengan efectos beneficiosos del tratamiento y no hayan sufrido progresión de la enfermedad ni cumplido cualquier criterio de retirada del estudio. Los sujetos que interrumpan el tratamiento con SD o una situación mejor pueden ser elegibles máximo de 1 año ,17 infusiones, si experimentan progresión después de interrumpir el tratamiento combinado del estudio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-06-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-06-15
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-08-16
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:59:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA